Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Ovarian cancer is often limited to the peritoneal cavity in the form of peritoneal carcinomatosis. Peritoneal spreading offers the opportunity for locoregional delivery of combinations of immunotherapy agents, maximizing bioavailability while potentially reducing systemic exposure and side effects. See related article by Orr et al., p. 2038.

More information

DOI

10.1158/1078-0432.ccr-22-0201

Type

Journal article

Publication Date

01/05/2022

Volume

28

Pages

1993 - 1995

Total pages

2

Addresses

Immunology and Immunotherapy Research Program, Cima Universidad de Navarra, Pamplona, Navarra, Spain.

Keywords

Humans, Peritoneal Neoplasms, Ovarian Neoplasms, Chemokines, Ligands, Immunotherapy, Female, Receptors, CXCR3, Carcinoma, Ovarian Epithelial